Last updated on April 2018

IVIg to Treat BK Viremia in Kidney Transplant Recipients


Brief description of study

The overall goal of this study is to rapidly improve clearance of BK viremia with Immunoglobulin (Privigen) thereby decreasing the potential for formation of alloantibodies in renal transplant recipients that have had immunosuppression reduction due to BK viremia. Our approach is to perform a prospective, randomized, placebo controlled trial intravenous immune globulin (IVIg; Privigen) plus protocolized immunosuppression reduction versus placebo and protocolized immunosuppression reduction in patients with BK viremia post-kidney transplantation.

Clinical Study Identifier: NCT02659891

Contact Investigators or Research Sites near you

Start Over

David Wojciechowski, DO

Massachusetts General Hospital
Boston, MA United States
  Connect »

Sabrina Tan, MD

Beth Israel Deaconess Medical Center
Boston, MA United States
  Connect »